A Randomized Trial of the Effect of Statin and Fibrate Therapy on Arterial Function in CKD

American Journal of Kidney Diseases

Volumn 49, Issue 6, 2007, Pages 776-785

  Dogra, Gursharan ^a,b   Irish, Ashley ^b   Chan, Dick ^a   Watts, Gerald ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

arterial compliance; Chronic kidney disease; dyslipidemia; endothelial function; fibrate; statin

Indexed keywords

ATORVASTATIN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; PREDNISOLONE;

ADULT; AGED; ARTERY COMPLIANCE; ARTICLE; BLOATING; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NAUSEA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AGED; ANTILIPEMIC AGENTS; BRACHIAL ARTERY; DOUBLE-BLIND METHOD; ELASTICITY; ENDOTHELIUM, VASCULAR; FEMALE; GEMFIBROZIL; GLOMERULAR FILTRATION RATE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME;

EID: 34249111937     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.03.003     Document Type: Article

References (44)

1. Baigent C., Burbury K., and Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 356 (2000) 147-152
2. Lowrie E.G., and Lew N.L. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15 (1990) 458-482
3. Liu Y., Coresh J., Eustace J.A., et al. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 291 (2004) 451-459
4. Tonelli M., Isles C., Curhan G.C., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110 (2004) 1557-1563
5. Tonelli M., Collins D., Robins S., et al. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am J Kidney Dis 44 (2004) 832-839
6. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
7. Isbel N.M., Haluska B., Johnson D.W., et al. Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. Am Heart J 151 (2006) 745-753
8. Rakhit D.J., Marwick T.H., Armstrong K.A., et al. Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. Heart 92 (2006) 1402-1408
9. Blacher J., Guerin A.P., Pannier B., et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38 (2001) 938-942
10. Yeun J.Y., and Kaysen G.A. C-Reactive protein, oxidative stress, homocysteine, and troponin as inflammatory and metabolic predictors of atherosclerosis in ESRD. Curr Opin Nephrol Hypertens 9 (2000) 621-630
11. Irish A.B., and Green F.R. Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: Relationship with dyslipidaemia, inflammation, and factor VII genotype. Nephrol Dial Transplant 13 (1998) 679-684
12. Treasure C.B., Klein J.L., Weintraub W.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332 (1995) 481-487
13. Dogra G.K., Watts G.F., Chan D.C., et al. Statin therapy improves brachial artery vasodilator function in patients with type 1 diabetes and microalbuminuria. Diabet Med 22 (2005) 239-242
14. Vaughan C.J., Gotto Jr. A.M., and Basson C.T. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35 (2000) 1-10
15. Irish A.B., and Thompson C.H. The effects of gemfibrozil upon the hypercoagulable state in dyslipidaemic patients with chronic renal failure. Nephrol Dial Transplant 11 (1996) 2223-2228
16. Watts G.F., and Dimmitt S.B. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 10 (1999) 561-574
17. Rubanyi G.M. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 22 suppl 4 (1993) S1-S14
18. Suwaidi J.A., Hamasaki S., Higano S.T., et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101 (2000) 948-954
19. Neunteufl T., Heher S., Katzenschlager R., et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 86 (2000) 207-210
20. Schachinger V., Britten M.B., and Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 (2000) 1899-1906
21. Celermajer D.S., Sorensen K.E., Gooch V.M., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340 (1992) 1111-1115
22. Woodman R.J., and Watts G.F. Measurement and application of arterial stiffness in clinical research: Focus on new methodologies and diabetes mellitus. Med Sci Monit 9 (2003) RA81-RA89
23. Grey E., Bratteli C., Glasser S.P., et al. Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. Am J Hypertens 16 (2003) 265-269
24. London G.M., Guerin A.P., Marchais S.J., et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 50 (1996) 600-608
25. London G.M. Arterial function in renal failure. Nephrol Dial Transplant 13 suppl 4 (1998) S12-S15
26. Blacher J., Safar M.E., Guerin A.P., et al. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 63 (2003) 1852-1860
27. London G.M., Blacher J., Pannier B., et al. Arterial wave reflections and survival in end-stage renal failure. Hypertension 38 (2001) 434-438
28. Tsunekawa T., Hayashi T., Kano H., et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 104 (2001) 376-379
29. McVeigh G.E., Brennan G.M., Cohn J.N., et al. Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus. Arterioscler Thromb 14 (1994) 1425-1429
30. Nestel P.J., Pomeroy S.E., Sasahara T., et al. Arterial compliance in obese subjects is improved with dietary plant n-3 fatty acid from flaxseed oil despite increased LDL oxidizability. Arterioscler Thromb Vasc Biol 17 (1997) 1163-1170
31. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis Model Assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
32. Woodman R.J., Playford D.A., Watts G.F., et al. Improved analysis of brachial artery ultrasound using a novel edge-detection software system. J Appl Physiol 91 (2001) 929-937
33. Dogra G., Irish A., Chan D., et al. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis 48 (2006) 926-934
34. Fathi R., Isbel N., Short L., et al. The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. Am J Kidney Dis 43 (2004) 45-52
35. Ichihara A., Hayashi M., Ryuzaki M., et al. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 17 (2002) 1513-1517
36. Holdaas H., Fellstrom B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 361 (2003) 2024-2031
37. Baigent C., and Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 84 (2003) S207-S210
38. Seliger S.L., Weiss N.S., Gillen D.L., et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61 (2002) 297-304
39. Mason N.A., Bailie G.R., Satayathum S., et al. HMG-coenzyme A reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 45 (2005) 119-126
40. Jardine A.G., Holdaas H., Fellstrom B., et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: Post-hoc subgroup analyses of the ALERT Study. Am J Transplant 4 (2004) 988-995
41. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360 (2002) 7-22
42. Shinohara K., Shoji T., Emoto M., et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 13 (2002) 1894-1900
43. London G.M., Guerin A.P., Marchais S.J., et al. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18 (2003) 1731-1740
44. Alaupovic P., Attman P.O., Knight-Gibson C., et al. Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency. Kidney Int 69 (2006) 1865-1871